A detailed history of Cerity Partners LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Cerity Partners LLC holds 432,382 shares of ALLO stock, worth $981,507. This represents 0.0% of its overall portfolio holdings.

Number of Shares
432,382
Previous 432,150 0.05%
Holding current value
$981,507
Previous $1.01 Million 20.28%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.08 - $3.5 $482 - $812
232 Added 0.05%
432,382 $1.21 Million
Q2 2024

Aug 13, 2024

BUY
$2.23 - $4.38 $17,797 - $34,956
7,981 Added 1.88%
432,150 $1.01 Million
Q1 2024

May 14, 2024

SELL
$2.92 - $5.63 $272,763 - $525,909
-93,412 Reduced 18.05%
424,169 $1.9 Million
Q4 2023

Jan 26, 2024

BUY
$2.28 - $3.5 $1.18 Million - $1.81 Million
517,581 New
517,581 $1.66 Million
Q2 2023

Aug 14, 2023

SELL
$4.53 - $6.74 $8,851 - $13,169
-1,954 Reduced 0.33%
598,100 $2.97 Million
Q1 2023

May 11, 2023

BUY
$4.92 - $8.21 $53,136 - $88,668
10,800 Added 1.83%
600,054 $2.96 Million
Q4 2022

Feb 15, 2023

SELL
$5.62 - $11.11 $231,381 - $457,409
-41,171 Reduced 6.53%
589,254 $3.71 Million
Q3 2022

Nov 10, 2022

BUY
$10.32 - $17.28 $303,521 - $508,222
29,411 Added 4.89%
630,425 $6.81 Million
Q2 2022

Aug 10, 2022

SELL
$6.78 - $12.28 $678,264 - $1.23 Million
-100,039 Reduced 14.27%
601,014 $6.85 Million
Q1 2022

Apr 25, 2022

SELL
$7.65 - $15.29 $17,847 - $35,671
-2,333 Reduced 0.33%
701,053 $6.39 Million
Q4 2021

Feb 14, 2022

BUY
$13.13 - $24.52 $4.01 Million - $7.49 Million
305,334 Added 76.71%
703,386 $10.5 Million
Q3 2021

Oct 25, 2021

SELL
$21.01 - $27.64 $44,121 - $58,044
-2,100 Reduced 0.52%
398,052 $10.2 Million
Q2 2021

Aug 11, 2021

SELL
$23.49 - $35.8 $34,060 - $51,909
-1,450 Reduced 0.36%
400,152 $10.4 Million
Q1 2021

Aug 11, 2021

BUY
$25.79 - $39.02 $10.4 Million - $15.7 Million
401,602 New
401,602 $14.2 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.